聚乙二醇干扰素在核苷（t） - 类似物 - 治疗的慢性乙型肝炎

StephenW

Source: J Viral Hepat  |  Posted 4 days ago
The role of peginterferon in nucleos(t)ide-analogue-treated chronic hepatitis B patients: a review of published literature; Zhang W, Xie Q, Ning Q, Dou X, Chen X, Jia J, Xie Y, Ren H; Journal of Viral Hepatitis (Feb 2017)

Chronic hepatitis B infection (CHB) causes up to 1.0 million deaths annually. Currently, more than 90% of CHB patients worldwide are receiving indefinite nucleos(t)ide analogue (NA) therapy. New strategies for optimizing hepatitis B surface antigen (HBsAg) loss are required for NA-treated patients as the majority are unable to achieve HBsAg loss and may require lifelong therapy. In hepatitis B e antigen (HBeAg)-positive patients, switching from NAs to finite peginterferon (PegIFN) therapy can double HBeAg seroconversion rates. One in five patients who switch to PegIFN can achieve HBsAg loss, whereas patients who continue NA therapy typically do not. In HBeAg-negative NA-treated patients, add-on PegIFN therapy achieves higher, albeit modest, HBsAg loss rates compared to continued NA monotherapy and offers the opportunity for NA-treated patients to achieve the inactive carrier state. In the absence of curative therapies, PegIFN represents a valuable, finite option for NA-treated patients who would otherwise require potentially lifelong therapy. This article is protected by copyright. All rights reserved.

StephenW

资料来源：J Viral Hepat |发布于4天前
聚乙二醇干扰素在核苷（t） - 类似物 - 治疗的慢性乙型肝炎患者中的作用：公开文献综述;张炜，谢Q，宁Q，杜旭，陈旭，贾杰，谢Y，任浩;病毒性肝炎杂志（2017年2月）

慢性乙型肝炎感染（CHB）每年导致高达100万人死亡。目前，全世界超过90％的CHB患者接受不确定的核苷类似物（NA）治疗。 NA治疗的患者需要用于优化乙型肝炎表面抗原（HBsAg）损失的新策略，因为大多数患者不能实现HBsAg消耗，并且可能需要终身治疗。在乙型肝炎e抗原（HBeAg）阳性患者，从NAs切换到有限聚乙二醇干扰素（PegIFN）治疗可以双重HBeAg血清转换率。五分之一的患者切换到PegIFN可以达到HBsAg的损失，而继续NA治疗的患者通常不会。在HBeAg阴性NA治疗的患者中，与继续NA单一疗法相比，加入的PegIFN治疗实现了更高的，虽然适度的HBsAg损失率，并且为NA-治疗的患者实现不活动载体状态提供了机会。在没有治疗性治疗的情况下，PegIFN代表了NA治疗的患者的有价值的有限选择，否则其需要潜在的终身治疗。本文受版权保护。版权所有。